Publicly traded German biotech company developing first-in-class Peptides in the Respiratory, Ophthalmology, Autoimmune and Hematology therapeutic areas.
Destum Partners leveraged several resources to achieve our clients goals:
• Primary Market Research: KOLs were interviewed to validate positioning strategy
• Secondary Market Research: Extensive literature review, public domain analysis and syndicated data synthesis occurred
• Valuation: Risk adjusted net present value ( rNPV ) methodology & transaction comps
• Internal Expertise: Several consulting projects completed in the therapeutic areas of interest to our Client
Summary and Results
Destum was engaged to select the optimal asset/indication strategy to reach key value inflection points & identify pathways to strategically deploy capital maximize the portfolio value.
The first phase involved Destum embarking on an extensive literature review of 35 potential indications. Emphasis was placed on differentiation of our Clients technology, target & disease biology, and clinical & commercial viability. Destum created a unique asset prioritization matrix to evaluate and rank all possible options. Destum’s analysis resulted in selecting three (3) programs with a total of 8 indications which were further assessed.
The second phase focused on formulating a TPP for each indication, identifying a positioning strategy, developing a granular clinical development plan (trial design & costs), and commercial forecast. Destum‘s customized rNPV valuation model was designed to isolate key value inflection points and correlate capital deployment with ROI.
Destum Partners strategic recommendations were accepted by our Client & their BOD; the final deliverable continues to serve as a core driver guiding our Clients corporate strategy.